News


 

 

BRIAN MEHLING, MD AND BHI THERAPEUTIC SCIENCES
TO PRESENT RESEARCH AT AAOS ANNUAL MEETING

Orthopedic surgeon Brian Mehling, MD and his research team at BHI Therapeutic Sciences will exhibit at the American Academy of Orthopedic Surgeons 2020 Annual Meeting, March 24 – 28, at the Orange County Convention Center in Orlando, Florida.

The team will present the results of their study entitled “Adipose Tissue-Derived Stromal Vascular Fraction Cells Application in Subjects with Osteoarthritis and Rheumatoid Arthritis: Retrospective Chart Review Study.” Their results will be presented at booth #1004 located in the West Concourse of the convention center.

“Musculoskeletal disorders are one of the most common reasons that patients seek medical care. The most common musculoskeletal problems are osteoarthritis and rheumatoid arthritis, said Dr. Mehling. “Adipose tissue-derived Stromal Vascular Fraction (SVF) cell therapy is a promising therapeutic option for rheumatoid arthritis and osteoarthritis,” he added.

Dr. Mehling and his team conducted the current retrospective chart review study to analyze the therapeutic efficacy of SVF cells administration in 350 subjects with rheumatoid arthritis and osteoarthritis. In the period from 2015 to 2018, 350 subjects received an intra- articular injection of autologous SVF cells at the Malacky Hospital (Bratislava, Slovakia). The hospital is fully licensed by the Ministry of Health of the Slovak Republic to offer cord blood, bone marrow and adipose stem cell derived treatments at Malacky Hospital in Bratislava, Slovakia. The study was approved by the Ministry of Health of the Slovak Republic and by the Institutional Review Board of the Institute of Regenerative and Cellular Medicine (IRCM-2017- 137).

“Charts were reviewed, and information from subjects’ pain and mobility assessment scales, conducted seven days, three, six and 12 months after therapy, was collected in the data collection forms,” said Marina Manvelyan, Ph.D., clinical research scientist, BHI Therapeutic Sciences.   

Assessment of pain and mobility was conducted seven days, three, six and 12 months after SVF cell therapy. Significant decrease in subjects’ pain levels and improvement in mobility were observed three, six and 12 months compared to seven days after therapy. The therapy demonstrated a strong safety profile with no severe adverse events or complications reported.

Dr. Mehling is a practicing American orthopedic trauma surgeon and researcher. He is spearheading groundbreaking research in stem cell therapy. Notably, BHITS is currently engaged in an FDA Investigational New Drug trial for stroke, using human umbilical cord blood (hUCB) stem cells.


Dr. Mehling started his path in medicine through undergraduate study at Harvard University, obtaining his Bachelor of Arts and Master of Science degrees in Biochemistry from Ohio State University.


Completing his degree of medicine at Wright State University School of Medicine, Dr. Mehling received post graduate education through residencies and fellowships at St. Joseph’s Hospital in Paterson, NJ and the Graduate Hospital in Philadelphia, PA, while pursuing a Ph.D. in Chemistry (which he is currently completing at Seton Hall University).


Dr. Mehling operates practices in northern New Jersey and Long Island, New York where he is on staff at Good Samaritan Hospital, Hackensack University Medical Center, Hackensack University Medical Center at Pascack Valley, Hackensack Meridian Palisades Medical Center, Hudson Regional Hospital, St. Joseph’s Medical Center, and St. Joseph’s Wayne Medical Center.

Founded in 1933, the Academy is the preeminent provider of musculoskeletal education to orthopaedic surgeons and others in the world. Its continuing medical education activities include a world-renowned Annual Meeting, multiple CME courses held around the country and at the Orthopaedic Learning Center, and various medical and scientific publications and electronic media materials.

 

 

BRIAN MEHLING, MD AND MARINA MANVELYAN, PH.D RECEIVE MEMBERSHIP

TO THE PRESTIGIOUSINTERNATIONAL SOCIETY FOR STEM CELL RESEARCH

Hackensack, NJ – BHI Therapeutic Sciences is pleased to announce that Brian Mehling, MD, Chief Medical Officer and Marina Manvelyan, Ph.D., Clinical Research Scientist have been accepted as members of the prestigious International Society for Stem Cell Research (ISSCR).

Members of the ISSCR have been sharing global stem cell science for more than 15 years. With roughly 4,000 members from more than 60 countries, the ISSCR is the pre-eminent global, cross-disciplinary, science-based organization dedicated to stem cell research and its translation to the clinic. The organization promotes global collaboration among the world’s most talented and committed stem cell scientists and physicians, and plays a catalyzing role in the development of effective new treatments.

According to George Q. Daley, MD, Ph.D., dean, Harvard Medical School and professor, Boston Children’s Hospital & Dana Farber Cancer Institute, “Core strengths of the ICCSR include its scientific integrity and excellence, and its outstanding membership comprised of research leaders worldwide.”

Dr. Mehling is the founder and chief medical officer of BHI Therapeutic Sciences.  He is a practicing American orthopedic trauma surgeon, researcher, and philanthropist. He is spearheading groundbreaking research in stem cell therapy focused on treatment and research using stem cells.

“We are focused on bringing advanced stem cell therapies within reach of a wider audience, “said Dr. Mehling. We envision a future in which stem cells are preferred over many surgical, pharmacological, and rehabilitative medical services,” he added.


Dr. Mehling and his colleagues are conducting clinical investigations to evaluate the safety and efficacy of adult stem cells in therapy of chronic inflammation, musculoskeletal conditions, stroke, spinal cord injury and other medical conditions.

Dr. Manvelyan has 15 years of experience in biomedical research and is the author of more than 40 research papers.

She started her research career as a research scientist at Yerevan State University (Armenia) and University Hospital of Jena, Institute of Human Genetic (Germany).

As a Clinical Research Scientist at BHI Therapeutic Sciences, she is conducting scientific research and clinical investigations of adult stem cell therapy for various medical conditions.

The ISSCR promotes the highest scientific and ethical standards and is dedicated to integrity in the rigor and quality of the research community’s scientific work.

BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells.   Its stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice. Results show its cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders and other medical conditions. Multiple studies of umbilical cord blood derived stem cell therapies and adipose-derived stem cell therapies are currently under investigation in clinical trials for a wide-range of medical conditions and show promising results. The Food and Drug Administration (FDA) has given BHITS approval to proceed with an Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke. For more information, please visit www.bhisciences.com

 

 

BRIAN MEHLING, MD TO PRESENT SPINAL CORD STEM CELL RESEARCH AT ANNUAL MEETING OF THE SOCIETY FOR BRAIN MAPPING AND THERAPEUTICS

Brian Mehling, MD has been invited to present his research at the 17th Annual World Congress of the Society for Brain Mapping and Therapeutics being held at the JW Marriott, in Los Angeles, California from Friday March 20 - Sunday, March 22.

The conference will bring together physicians, scientists, policy makers, funding agencies and industry to further the advances and applications in brain and spinal cord mapping and image guide therapies (operative and non-operative).

Dr. Mehling is the founder and chief medical officer of BHI Therapeutic Sciences. He is a practicing American orthopedic trauma surgeon, researcher, and philanthropist. He is spearheading groundbreaking research in stem cell therapy focused on treatment and research using stem cells.

His presentation is entitled Umbilical Cord Blood Stem Cell Therapy for Spinal Cord Injury and the objective of this retrospective cohort study was to analyze the muscle, nerve, urinary, and gastrointestinal function in subjects with spinal cord injury, treated with either human umbilical cord blood-derived mononuclear cells or conventional therapy. "Allogeneic umbilical cord blood mononuclear cell therapy in 30 subjects with spinal cord injury showed significant improvement in pain and temperature sensation, lower limb muscle strength, bladder function, and gastrointestinal function compared to a conventional therapy group," Dr. Mehling said.

"We are focused on bringing advanced stem cell therapies within reach of a wider audience," said Dr. Mehling. We envision a future in which stem cells are preferred over many surgical, pharmacological, and rehabilitative medical services," he added.

Dr. Mehling and his colleagues are conducting clinical investigations to evaluate the safety and efficacy of adult stem cells in therapy of chronic inflammation, musculoskeletal conditions, stroke, spinal cord injury and other medical conditions.

BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells. Its stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice. Results show its cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders and other medical conditions. Multiple studies of umbilical cord blood derived stem cell therapies and adipose-derived stem cell therapies are currently under investigation in clinical trials for a wide-range of medical conditions and show promising results. The Food and Drug Administration (FDA) has given BHITS approval to proceed with an Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke. For more information, please visit www.bhisciences.com.

The Society for Brain Mapping and Therapeutics (SBMT) is a non-profit society organized for the purpose of encouraging basic and clinical scientists who are interested in areas of Brain Mapping, engineering, stem cell, nanotechnology, imaging and medical device to improve the diagnosis, treatment and rehabilitation of patients afflicted with neurological disorders.

This society promotes the public welfare and improves patient care through the translation of new technologies/therapies into lifesaving diagnostic and therapeutic procedures. The society is committed to excellence in education, and scientific discovery. The society achieves its mission through multi-disciplinary collaborations with government agencies, patient advocacy groups, educational institutes and industry as well as philanthropic organization.

Our Locations

Choose your preferred location